Most solid tumors are unable to grow in the ascites form, unless selected by prolonged serial transfer of peritoneal¯uid (Klein, 1955). Established ascites tumor cells grow under highly crowded, virtually anoxic conditions (Warburg and Hiepler, 1953) . Hypoxia was recently identi®ed as a powerful inducer of p53 dependent apoptosis (Graeber et al., 1996). We wished to examine whether the conversion of relatively wellvascularized solid mouse tumors into freely growing ascitic cell variants favors cell with mutated or deleted p53. We have sequenced exons 4 ± 9 of p53 cDNA from two serially transplanted methylcholanthrene induced sarcomas (MCIM and MSWBS) that were available in the original solid and the gradually converted ascites form. We have also examined ®ve additional solid tumors, four carcinomas and one sarcoma and six additional ascites tumors, ®ve carcinomas and one sarcoma. Sequence analysis showed that all solid tumors carried exclusively wild type p53. Among the eight ascites tumors, ®ve carried mutant p53 and three had only the wild type gene. In one of the two isogenic pairs, the original solid tumor line had only wild type, whereas the derived ascites line had only mutant p53. In the second pair, the solid tumor was wild type whereas the ascitic variant was heterozygous. The naturally occurring alternatively spliced p53 (p53as) mRNA was detected in all solid tumors, but not in ®ve of the eight ascites tumors. Our ®ndings indicate that conversion of solid into ascites tumors favors the selection of cell variants with mutated p53 and of cells that lack the alternatively spliced form of p53.
Introduction
Tumor development and progression is due to the accumulation of genetic and epigenetic changes that confer selective growth advantage on the cells. Many tumors show at least three types of genetic changes: oncogene activation that favors or drives cell proliferation, functional or structural inactivation of`bottleneck' suppressors, and mutations that increase the apoptotic threshold. Many apoptotic pathways are p53 dependent (Ko and Prives, 1996) . Cells exposed to hypoxia accumulate wild type p53 protein (Graeber et al., 1994) and readily succumb to apoptosis (Graeber et al., 1996) . Conceivably, hypoxia may favor mutant p53-carrying cells. In support of this notion, p53 negative cells can overgrow p53 positive cells in arti®cial mixtures, cultivated under hypoxic but not anaeorbic conditions (Graeber et al., 1996) .
Ascites tumor cells are known to grow under highly anaerobic conditions. Selective growth of hypoxia adapted cells is part of the ascites conversion. Solid tumor cells implanted into the peritoneal cavity of mouse do not grow immediately as free cells in the peritoneal¯uid. Freely growing ascites variants could be selected, however, from both carcinomas and sarcomas by serial passage of peritoneal¯uid from mice with i.p. implanted solid tumors (Klein, 1955a) . Once selected, the ability to grow in the ascitic¯uid remained stable, and did not revert after continuous passage as solid tumors (Klein, 1955b) .
Solid tumors are heterogeneous with respect to oxygen supply. Necrosis increases with the distance from the nearest capillary (Thomlinson and Gray, 1955) . When solid tumors are carried by serial passage in vivo, well-oxygenated cells have the best chance to survive and grow. The selective pressure that favors hypoxia resistant cells may not be very strong. Freely growing cells of the ascites tumor are more uniformly con®ned to the virtually anaerobic, highly crowded ascites¯uid (Warburg and Hiepler, 1953) , and may be therefore exposed to a much stronger selection.
The question arises whether this adaptation to anaerobic conditions may also involve p53 deletions or mutations that may make the cells less prone to hypoxia induced apoptosis. Our ®ndings indicate that this is the case. Unexpectedly we have also found that the ascitic variants often fail to express the alternatively spliced p53 transcript (Kulesz-Martin et al., 1994; Wu et al., 1997) .
Results

p53 cDNA detection by PCR
The full length p53 coding sequence was ampli®ed from cDNA. The regular p53 transcript was ampli®ed using the primers p53-cDNAF and p53-cDNAR producing an 1173 bp PCR product. The p53as transcript was ampli®ed using the primers p53-cDNAF and p53as-cDNA, generating an 1144 bp PCR product. A nested PCR with the primer pair E4F/E9R gave rise to a product of 875 bp, using the 1173 bp product as template. p53 transcripts were present in all tumors tested, although the Ehrlich and ELD ascites tumors generated a 76 bp shorter product than the normal one. The p53as transcript was detected in all seven solid tumors but in only three of the eight ascites tumors. In the remaining 55, the p53as transcript could not even be detected by nested PCR, using the primer pair E4F/E9R and the p53-cDNAF/ p53as-cDNA PCR product as template.
p53 is frequently mutated in ascites but not in solid tumors
Further characterization of the ampli®ed p53 transcripts was carried out, by sequencing either the p53-cDNAF/p53-cDNAR PCR product or the product derived from nested E4F/E9R PCR, using two sequencing primers, E4F2 and E6F, located in exon 4 and exon 6, respectively (Figure 1) . This permitted the analysis of the cDNA sequence that encodes amino acid residues 54 ± 320 of p53.
The sequencing results are shown in Table 1 . All 5 tumors listed in the upper section of the Table carried wild type p53 and were positive for both p53 and p53as. The mid section of Table 1 shows the comparisons between solid and ascites sublines of the same tumor, the MC1M trio and the MSWB/S pair. MC1M SS carried only wild type p53. The two ascites selected sublines MC1MM AA and its derivative, MC1M AS, carried the same p53 mutation and no wild type p53. The solid MSWB SS line contained only wild type p53, while MSWBS AA, the ascitic subline, had both mutated and wild type p53. All tumors in this group (mid section, Table 1 ) expressed both p53 and p53as transcripts.
Among the remaining ascites tumors (lower section, Table 1 ), three carried only wild type p53, and three carried mutant p53. Two mutations were detected in TA3-Hauschka (Table 1) , but it is unclear whether they reside in one or two separate alleles. Thus, TA3-Hauschka may carry both wild type and mutant p53, or two mutant alleles. Ehrlich and the derived ELD expressed shorter p53 transcripts lacking exon 9. Sequence analysis of genomic DNA revealed an A to C base substitution in the highly conserved, and carried dinucleotide, AG, the splice acceptor site of exon 9 (Green, 1986) . The deletion of exon 9 and joining of exon 8 and exon 10 leads to a frameshift that should generate a truncated 309 amino acid residue protein, containing p53 residues 1 ± 304, followed by ®ve new residues, Arg, Asp, Pro, Arg and Arg. No p53 protein could be detected by immunoprecipitation or immunouorescence, however (not shown). Both Ehrlich sublines expressed both types of p53 transcripts. Thus, all seven solid tumor lines tested carried only wild type p53, whereas ®ve out of eight ascites tumors and passaged as solid tumor over many years. **Since DNA sequencing revealed both wt and mutant sequence at indicated codons, TA3-Hauschka may carry one wt and one mutant allele or two mutant alleles. ***Deletion of exon 9 due to a splice acceptor site mutation Figure 1 Sequencing strategy. Designation and location of primers used for PCR and sequencing of murine p53 cDNA. Numbers in boxes indicate exons harbored p53 mutations. Moreover, all unmatched ascites tumors, except Ehrlich and ELD failed to express the p53as transcript. Since the three ascites tumors that expressed p53as all carried p53 mutation, the wild type p53as transcript is not present in any of the ascites tumors.
Discussion
The gradual conversion of solid into ascites tumors usually require 10 or more selective passages by serial transfer of peritoneal exudate (Klein and Klein, 1951) . The ability to grow in the¯uid form has several phenotypic correlates, such as decreased adhesiveness and the associated disseminating ability into distant organs (Ringertz et al., 1957) , increased surface charge (Purdom et al., 1958) and as Warburg has shown, a shifting of cellular metabolism to the anaerobic state. Warburg has suggested that this re¯ects a permanent adaptation to survival and growth under anaerobic or near anaerobic conditions (Warburg, 1956) . In view of the recent demonstration that hypoxia induces p53 dependent apoptosis (Graeber et al., 1996) we wished to examine whether the selection of ascites variants favored variants with mutated p53. We found that ®ve of eight ascites variants carried mutant p53 while all seven solid tumors examined only had wild type p53. This is consistent with our working hypothesis. In a study by Schumacker et al., (1997) , malignant ovarian cells from three patients were successfully transplanted serially intraperitoneally in SCID mice. The cells acquired p53 mutations during this process. In contrast, a recent study of matched samples of solid and ascites tumor cells from patients with ovarian cancer did not reveal any clear association between p53 mutation and ascites growth (Provencher et al., 1997) . It should be kept in mind, however, that the environment in the mouse peritoneal cavity is not comparable to that of the human peritoneal cavity. The number of cells growing in the peritoneal cavity of mice reaches 10 million, which greatly exceeds the number of cells in human ascites. Therefore, the selection pressure for p53 mutations in human ascites may be dierent from that in mouse ascites.
Solid tumors often contain necrotic areas. Thomlinson and Gray (1955) have shown that the prevalence of necrosis increase with distance from the nearest capillary. If so, why is there no selection for p53 mutations in the solid tumors? It may be surmised that serial transplantation in the solid form involves the selective survival of the most privileged cells, located closest to the capillary. In the ascites tumor, a morè democratic' situation prevails. All cells are exposed to the same hypoxic conditions, particularly if consideration is restricted to the random droplets of the ascitic uid, used to passage the tumor. The selection pressure that favors hypoxia-protective p53 mutation may be therefore much greater. This does not preclude that the p53 mutations may have other growth-facilitating eects as well, but it may be noted that the growth rate of the ascites adapted MC1M-AS and the original, solid SS subline did not dier in an earlier comparison (Ringertz et al., 1957) .
At least one ascites tumor, MSWBS, and possibly TA3-Hauschka, was heterozygous for p53 point mutations. It is conceivable that these tumors have lost their wild type p53 function. Mutant p53 can act in a dominant negative fashion to inactivate normal p53 function in tumor cells (Lavigueur and Bernstein, 1991) . We have previously demonstrated that polyomavirus induced tumors cells carrying both mutant and wild type fail to upregulate the two p53-responsive genes p21 WAF1 and MDM2 p53 in response to the DNA damaging agent mitomycin C (Qian et al., 1997) .
Interestingly, the alternatively spliced p53as transcript was present in all solid tumors but absent in ®ve out of eight ascites tumors. The p53 and p53as proteins are identical except for the C-terminal region. Therefore the mutations described in this study would aect both proteins. The p53as protein is constitutively active for sequence-speci®c DNA binding (Wu et al., 1994; Bayle et al., 1995; Wolkowicz et al., 1995) and accumulates following DNA damage in normal ®broblasts and kerotinocytes, in parallel with induction of p21 WAF1 (Wu et al., 1997) . Since the sequencespeci®c DNA binding of p53 is crucial for its tumor suppressor function, the p53as protein may be even more potent as tumor suppressor than the regular p53 protein. We have found that the p53as transcript is either mutated or missing in all ascites tumors. Loss of p53as in tumors has not been reported previously. Our Figure 2 PCR ampli®cation of p53 cDNA. p53 (lanes 1 ± 3) and p53as (lanes 4 ± 6) was ampli®ed using speci®c primers p53-cDNAF/p53-cDNAR and p53-cDNAF/p53as-cDNAR respectively (see Figure 1 results suggest that there is a strong selection against the expression of the wild type p53as protein during tumor development.
Materials and methods
Tumors
The origin, names and the relevant data of the tumor passage history are shown in Table 1 . The ascites tumors had been derived from solid carcinomas and sarcomas, gradually converted by serial transfer of peritoneal¯uid. Subsequently, they were maintained by serial intraperitoneal passage in syngeneic mice. The symbol SS designates tumors that have been passaged subcutaneously and were never inoculated i.p. AA designates ascites converted sublines. AS indicates solid tumors reconverted from the ascites line by subcutaneous inoculation and subsequently by subcutaneous transfer. The group of solid tumors studied consists of one sarcoma, MC57X, a methylcholanthrene induced tumor in C57B1 mouse (Klein et al., 1960) and four spontaneous mammary adenocarcinomas; SHG, SHJ and SHK obtained from C3H mice (Kuzumaki et al., 1980) , and SBfnHD, which was isolated from a CBA mouse, foster nursed on C3H (Kuzumaki et al., 1980) . Two isogenic tumor pairs are included. The MC1M and MSWB sarcomas were originally induced by methylcholanthrene in a C3H and an AxASW F1 mouse, respectively (Klein, 1955a; Ringertz et al., 1957) . The MC1M SS tumor was converted into the ascites form by 10 serial passages of peritoneal exudate. MSWBS was ®rst selected as a solid tumor subline of the original. MSWB sarcoma, induced in an AxASW F1 mouse by serial passage in the parental ASW strain. Subsequently, it was converted into the ascites form, designated MSWBS AA. Six unmatched ascites tumors were also included. S3A was originally a spontaneous mammary carcinoma from A/Snell mouse, converted to the ascites form (Klein, 1955b) . TA3-Sth and TA3-Hauschka are two serially transplanted ascites tumor lines from the spontaneous mammary adenocarcinoma TA3 of A/Snell strain origin (HellstroÈ m et al., 1978) . They have been separated for at least two decades. The MDAY sarcoma was induced by methylcholanthrene in AxDBA/ 2F1 and passaged 400 times in vivo (Klein et al., 1960) . The Ehrlich ascites tumor was originally a spontaneous mammary carcinoma, established in passage as a solid tumor allograft in 1896, converted to the ascites form early in this century and subsequently passaged with peritoneal¯uid (LettreÂ , 1950) . ELD is a subline of the Ehrlich ascites tumors separately maintained for at least 60 years. The two Ehrlich lines have dierent chromosomal constitutions. Ehrlich is near tetraploid and ELD is near diploid (Klein and Klein, 1951) . Krebs 2 is a mammary carcinoma derived ascites tumor (Klein and Klein, 1951) .
Isolation of DNA, RNA and RT ± PCR Genomic DNA was extracted by QIAamp Kit (QIAGEN GmbH, Germany) and total RNA by RNAzol B (AMS Biotechnology, USA) according to the manufacturer's protocol. First strand cDNA was synthesized in 20 ml using 1 ± 3 mg of total RNA, 25 units of M-MLV reverse transcriptase (Gibco ± BRL, USA), 20 mM dNTPs, 20 mM random 14 nucleotide oligomers and buer provided with the enzyme. For PCR ampli®cation the following primers were used; p53-cDNAF (5'-ACTGCCATGGAGGAGTC-ACA), p53-cDNAR (5'-CAGTCAGTCTGAGTCAGGC-CC), p53as-cDNAR (5'-GCTAGCAGTTTGGGCTTTC-CT), E4F (5'-CACTGCATGGACGATCTGTT), E9RB (5'-CGGATCTTGAGGGTGAAATA), and E7i7F (5'-TC-CAGGTAGGAAGGCGCGT). PCR ampli®cations were carried out on a Perkin Elmer 9600 thermocycler in a volume of 50 ml, using 1 ml of the cDNA templates, 10 pmole of each primer, 2.5 mM MgCl 2 2.5 mM dNTPs, 1 U of AmpliTaq polymerase (Perkin Elmer, USA) or 0.1 U of Red Hot polymerase (Advanced Biotechnology Ltd., UK), and buers provided with the enzymes. The ®rst cycle was performed at 958C for 3 min, followed by 30 cycles at 958C for 15 s, 608C for 20 s and 728C for 30 s. The reactions were completed at 728C for 7 min.
DNA sequencing
Direct sequencing was performed using the Thermo Sequenase¯uorescent labeled cycle sequencing kit (Amersham, UK), with three 5'¯uorescently labeled primers E4F2 (5'-CCCAGGATGTTGAGGAGTTT), E6F (5'-CT-CCTCCCCAGCATCTTATC) and E8F (5'-GAGGTT-CGTGTTTGTGCCTG) (Pharmacia, Sweden, and Biosource, Belgium). Six ml of a mastermix, containing 200 ng of PCR template, 10 pmol of¯uorescent primer and ddH20 in a ®nal volume of 24 ml, was added to 2 ml of termination mixes (A, C, G and T respectively) and cycle sequencing was carried out on a Perkin Elmer 9600. An initial denaturation step at 958C for 3 min was followed by 35 cycles of 948C for 15 s, 588C for 30 s, 728C for 1 min and a ®nal extension at 728C for 7 min. Four ml of stop solution was added, and 6 ml of the samples was subsequently loaded on a 6.75% acrylamide gel (Readymix, Pharmacia) and run for 570 min at 428C on a automated DNA sequencer (ALF, Pharmacia). The sequences were analysed using the ALFwin software 1.1 (Pharmacia)
